

CHANGES IN LIVER METABOLISM INDICATORS IN AIGA

**Kurbanova Z.Ch.,
Khushbokova G.U.**
Tashkent

Abstract: *This study comprehensively studied the metabolic dysfunction of the liver and specific changes in laboratory tests in patients with AIGA. The main emphasis was on elucidating the changes in total protein concentration during metabolic processes.*

Relevance: Autoimmune hemolytic anemia is an acquired, heterogeneous disease that causes premature destruction of erythrocytes under the influence of autoantibodies against erythrocytes. The pathogenesis of AIGA is not fully understood. AIGA is a chronic and slowly progressive disease, and in 40% of patients, clinical symptoms are not observed at the time of diagnosis, and it is possible to detect it through changes in liver metabolism.

Objective: To study the dynamics of changes in liver metabolism in patients with AIG.

Materials and methods: 60 patients diagnosed with AIIG in the multidisciplinary clinic of TDTU were divided into three groups depending on the duration of the disease. Group 1 included 30 patients (up to 6 months), group 2 included 19 patients (from 6 months to 2 years), and group 3 included 11 patients (from 2 to 4 years). The control group consisted of 10 patients. In these groups, autoimmune hepatitis positive and autoimmune hepatitis negative patients were divided into subgroups.

Results and discussion: Total serum protein levels were almost identical in the study groups (75.02–75.34 g/l) and in the AIH+ subgroups

(70.92–75.10 g/l) to the control group (70.88 g/l). The absence of statistical differences between and within groups confirms that the presence of autoimmune hepatitis does not significantly affect the total serum protein concentration and that this indicator is stable.

Conclusion: The results of the study show that the total protein content in the main groups does not differ statistically significantly from the control group. The stability of the indicators even in the AIH+ subgroup confirms that the development of autoimmune processes does not have a significant negative impact on the protein synthesis activity of the liver at this stage.

REFERENCES

1. Barcellini W. et al. New insights in autoimmune hemolytic anemia: from pathogenesis to therapy //Journal of clinical medicine. – 2020. – T. 9. – №. 12. – C. 3859.
2. Michalak S. S. et al. Autoimmune hemolytic anemia: current knowledge and perspectives //Immunity & Ageing. – 2020. – T. 17. – №. 1. – C. 38.
3. Michel M. et al. Autoimmune haemolytic anaemias //Nature Reviews Disease Primers. – 2024. – T. 10. – №. 1. – C. 82.